ALK-Abelló A/S (AKABY) Research

ALK-Abelló A/S operates as a global leader in allergy solutions, serving markets across Europe, North America, and internationally. The company provides a diverse range of allergy immunotherapy (AIT) products, offered as injections, sublingual drops, and tablets, specifically formulated to address common allergies like house dust mite, grass, tree pollen, ragweed, and Japanese cedar. In addition to these therapeutic options, ALK-Abelló manufactures adrenaline auto-injectors for emergency treatment of severe allergic reactions and produces diagnostic tools for allergy identification. Prominent products for allergic rhinitis include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX. ACARIZAX, another key offering, targets both allergic rhinitis and allergic asthma. Established in 1923, ALK-Abelló A/S is headquartered in Hørsholm, Denmark.

Market snapshot

Symbol
AKABY
Price
$90.00
Day change
0.00%
Market cap
$55.4B
P/E ratio
43.33x
52-week range
90-90
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Abcam plc (ABCZF)
  • Alpine Immune Sciences, Inc. (ALPN)
  • Arena Pharmaceuticals, Inc. (ARNA)
  • Churchill Capital Corp XI (CCXI)
  • Global Blood Therapeutics, Inc. (GBT)
  • IVERIC bio, Inc. (ISEE)
  • Mirati Therapeutics, Inc. (MRTX)
  • Reata Pharmaceuticals, Inc. (RETA)

Open ALK-Abelló A/S (AKABY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.